Viehbacher assessing BD as Biogen ‘rebalances’ risk, reward in pipeline

As new CEO Christopher Viehbacher seeks to rebalance risk and potential reward in Biogen’s pipeline, the company could look to deals for innovative products that will help drive its return to growth.

During the company’s 4Q22 and full-year earnings call Wednesday, Viehbacher said Biogen Inc. (NASDAQ:BIIB) could further explore “external growth opportunities” in immunology, rare diseases or psychiatry. The company is looking to hire a head of business development, as well as a head of research; it has split its top R&D role in two positions, with Priya Singhal now serving as head of development...